These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20150632)

  • 21. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A; Shin DM; El-Rayes B; Khuri FR; Kauh JS
    Br J Cancer; 2013 Mar; 108(4):762-5. PubMed ID: 23322195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
    Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
    Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
    Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Ramirez PT; Landen CN; Coleman RL; Milam MR; Levenback C; Johnston TA; Gershenson DM
    Gynecol Oncol; 2008 Jan; 108(1):68-71. PubMed ID: 17905421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
    Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
    Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Lee J; Suh C; Kang HJ; Ryoo BY; Huh J; Ko YH; Eom HS; Kim K; Park K; Kim WS
    Ann Oncol; 2008 Dec; 19(12):2079-83. PubMed ID: 18689866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
    Hensley ML; Dizon D; Derosa F; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Colevas AD; Spriggs D; Aghajanian C
    Invest New Drugs; 2007 Aug; 25(4):335-41. PubMed ID: 17364235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
    Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
    Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
    Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
    Mendler JH; Kelly J; Voci S; Marquis D; Rich L; Rossi RM; Bernstein SH; Jordan CT; Liesveld J; Fisher RI; Friedberg JW
    Ann Oncol; 2008 Oct; 19(10):1759-64. PubMed ID: 18504251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
    Dudek AZ; Larson T; Keshtgarpour M; Kumar P
    Am J Clin Oncol; 2007 Oct; 30(5):481-6. PubMed ID: 17921707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.